Is human papillomavirus genotype an influencing factor on radiotherapy outcome? Ambiguity caused by an association of HPV 18 genotype and adenocarcinoma histology

Journal of Gynecologic Oncology

Volumn 22, Issue 1, 2011, Pages 32-38

  Kim, Joo Young ^a   Nam, Byung Ho ^a   Lee, Jin Ah ^a  

^a National Cancer Center   (South Korea)

Author keywords

Adenocarcinoma; Adenosquamous carcinoma; Human papillomavirus 18; Radiotherapy outcome; Uterine cervical cancer

Indexed keywords

CISPLATIN; FLUOROURACIL;

ADENOCARCINOMA; ADENOSQUAMOUS CARCINOMA; ARTICLE; BRACHYTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; GENOTYPE; HISTOPATHOLOGY; HPV REVERSE HYBRIDIZATION LINE PROBE ASSAY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 18; HYBRIDIZATION; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; PAPILLOMAVIRUS INFECTION; POLYMERASE CHAIN REACTION; PROGNOSIS; RECURRENCE RISK; TREATMENT OUTCOME; UTERINE CERVIX CARCINOMA;

EID: 79954502633     PISSN: 20050380     EISSN: 20050399     Source Type: Journal    
DOI: 10.3802/jgo.2011.22.1.32     Document Type: Article

References (38)

1. Burger RA, Monk BJ, Kurosaki T, Anton-Culver H, Vasilev SA, Berman ML, et al. Human papillomavirus type 18: association with poor prognosis in early stage cervical cancer. J Natl Cancer Inst 1996;88:1361-8.
2. Fujiwara H, Mitchell MF, Arseneau J, Hale RJ, Wright TC Jr. Clear cell adenosquamous carcinoma of the cervix: an aggressive tumor associated with human papillomavirus-18. Cancer 1995;76:1591-600.
3. Kitagawa K, Yoshikawa H, Onda T, Kawana T, Taketani Y, Yoshikura H, et al. Genomic organization of human papillomavirus type 18 in cervical cancer specimens. Jpn J Cancer Res 1996;87:263-8.
4. Lai CH, Chang CJ, Huang HJ, Hsueh S, Chao A, Yang JE, et al. Role of human papillomavirus genotype in prognosis of early-stage cervical cancer undergoing primary surgery. J Clin Oncol 2007;25:3628-34.
5. Lombard I, Vincent-Salomon A, Validire P, Zafrani B, de la Rochefordiere A, Clough K, et al. Human papillomavirus genotype as a major determinant of the course of cervical cancer. J Clin Oncol 1998;16:2613-9.
6. Im SS, Wilczynski SP, Burger RA, Monk BJ. Early stage cervical cancers containing human papillomavirus type 18 DNA have more nodal metastasis and deeper stromal invasion. Clin Cancer Res 2003;9:4145-50.
7. Kim JY, Park S, Nam BH, Roh JW, Lee CH, Kim YH, et al. Low initial human papilloma viral load implicates worse prognosis in patients with uterine cervical cancer treated with radiotherapy. J Clin Oncol 2009;27:5088-93.
8. Andersson S, Rylander E, Larson B, Sigurdardottir S, Backlund I, Sallstrom J, et al. Types of human papillomavirus revealed in cervical adenocarcinomas after DNA sequencing. Oncol Rep 2003;10:175-9.
9. Iwasawa A, Nieminen P, Lehtinen M, Paavonen J. Human papillomavirus DNA in uterine cervix squamous cell carcinoma and adenocarcinoma detected by polymerase chain reaction. Cancer 1996;77:2275-9.
10. Schellekens MC, Dijkman A, Aziz MF, Siregar B, Cornain S, Kolkman-Uljee S, et al. Prevalence of single and multiple HPV types in cervical carcinomas in Jakarta, Indonesia. Gynecol Oncol 2004;93:49-53.
11. Tase T, Okagaki T, Clark BA, Manias DA, Ostrow RS, Twiggs LB, et al. Human papillomavirus types and localization in adenocarcinoma and adenosquamous carcinoma of the uterine cervix: a study by in situ DNA hybridization. Cancer Res 1988;48:993-8.
12. Tase T, Sato S, Wada Y, Yajima A, Okagaki T. Prevalence of human papillomavirus type 18 DNA in adenocarcinoma and adenosquamous carcinoma of the uterine cervix occurring in Japan. Tohoku J Exp Med 1988;156:47-53.
13. Teshima H, Beaudenon S, Koi S, Katase K, Hasumi K, Masubuchi K, et al. Human papillomavirus type 18 DNA sequences in adenocarcinoma and adenosquamous carcinoma of the uterine cervix. Arch Gynecol Obstet 1997;259:169-77.
14. Uchiyama M, Iwasaka T, Matsuo N, Hachisuga T, Mori M, Sugimori H. Correlation between human papillomavirus positivity and p53 gene overexpression in adenocarcinoma of the uterine cervix. Gynecol Oncol 1997;65:23-9.
15. Yamakawa Y, Forslund O, Teshima H, Hasumi K, Kitagawa T, Hansson BG. Human papillomavirus DNA in adenocarcinoma and adenosquamous carcinoma of the uterine cervix detected by polymerase chain reaction (PCR). Gynecol Oncol 1994;53:190-5.
16. Yoshida T, Sano T, Oyama T, Kanuma T, Fukuda T. Prevalence, viral load, and physical status of HPV 16 and 18 in cervical adenosquamous carcinoma. Virchows Arch 2009;455:253-9.
17. Reimers LL, Anderson WF, Rosenberg PS, Henson DE, Castle PE. Etiologic heterogeneity for cervical carcinoma by histopathologic type, using comparative age-periodcohort models. Cancer Epidemiol Biomarkers Prev 2009; 18:792-800.
18. Saint-Paul MT, Bremond A, Rochet Y. Cervical cancer before 35 years of age: epidemiological and prognostic aspects. Retrospective study of 46 cases of cervical cancer before 35 years of age in a series of 449 cases in stages IA2 and IV. J Gynecol Obstet Biol Reprod (Paris) 1993;22:737-42.
19. Barnes W, Delgado G, Kurman RJ, Petrilli ES, Smith DM, Ahmed S, et al. Possible prognostic significance of human papillomavirus type in cervical cancer. Gynecol Oncol 1988;29:267-73.
20. Ogura K, Ishi K, Matsumoto T, Kina K, Nojima M, Suda K. Human papillomavirus localization in cervical adenocarcinoma and adenosquamous carcinoma using in situ polymerase chain reaction: review of the literature of human papillomavirus detection in these carcinomas. Pathol Int 2006;56:301-8.
21. Lee MF, Chang MC, Wu CH. Detection of human pa pillomavirus types in cervical adenocarcinoma by the polymerase chain reaction. Int J Gynaecol Obstet 1998;63: 265-70.
22. Liebrich C, Brummer O, Von Wasielewski R, Wegener G, Meijer C, Iftner T, et al. Primary cervical cancer truly negative for high-risk human papillomavirus is a rare but distinct entity that can affect virgins and young adolescents. Eur J Gynaecol Oncol 2009;30:45-8.
23. Botezatu A, Socolov D, Goia CD, Iancu IV, Ungureanu C, Huica I, et al. The relationship between HPV16 and HPV 18 viral load and cervical lesions progression. Roum Arch Microbiol Immunol 2009;68:175-82.
24. Castellsague X, Diaz M, de Sanjose S, Munoz N, Herrero R, Franceschi S, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 2006;98:303-15.
25. Hildesheim A, Berrington de Gonzalez A. Etiology and prevention of cervical adenocarcinomas. J Natl Cancer Inst 2006;98:292-3.
26. Wheeler CM, Hunt WC, Joste NE, Key CR, Quint WG, Castle PE. Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Natl Cancer Inst 2009;101:475-87.
27. Eifel PJ, Burke TW, Delclos L, Wharton JT, Oswald MJ. Early stage I adenocarcinoma of the uterine cervix: treatment results in patients with tumors less than or equal to 4 cm in diameter. Gynecol Oncol 1991;41:199-205.
28. Eifel PJ, Burke TW, Morris M, Smith TL. Adenocarcinoma as an independent risk factor for disease recurrence in patients with stage IB cervical carcinoma. Gynecol Oncol 1995;59:38-44.
29. Eifel PJ, Morris M, Oswald MJ, Wharton JT, Delclos L. Adenocarcinoma of the uterine cervix: prognosis and patterns of failure in 367 cases. Cancer 1990;65:2507-14.
30. Kjorstad KE, Bond B. Stage IB adenocarcinoma of the cervix: metastatic potential and patterns of dissemination. Am J Obstet Gynecol 1984;150:297-9.
31. Kosary CL. FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Semin Surg Oncol 1994; 10:31-46.
32. Lea JS, Sheets EE, Wenham RM, Duska LR, Coleman RL, Miller DS, et al. Stage IIB-IVB cervical adenocarcinoma: prognostic factors and survival. Gynecol Oncol 2002;84: 115-9.
33. Matthews CM, Burke TW, Tornos C, Eifel PJ, Atkinson EN, Stringer CA, et al. Stage I cervical adenocarcinoma: prognostic evaluation of surgically treated patients. Gynecol Oncol 1993;49:19-23.
34. Nakanishi T, Ishikawa H, Suzuki Y, Inoue T, Nakamura S, Kuzuya K. A comparison of prognoses of pathologic stage Ib adenocarcinoma and squamous cell carcinoma of the uterine cervix. Gynecol Oncol 2000;79:289-93.
35. Reagan JW, Fu YS. Histologic types and prognosis of cancers of the uterine cervix. Int J Radiat Oncol Biol Phys 1979;5:1015-20.
36. Recoules-Arche A, Rouzier R, Rey A, Villefranque V, Haie-Meder C, Pautier P, et al. Does adenocarcinoma of uterine cervix have a worse prognosis than squamous carcinoma? Gynecol Obstet Fertil 2004;32:116-21.
37. Samlal RA, van der Velden J, Ten Kate FJ, Schilthuis MS, Hart AA, Lammes FB. Surgical pathologic factors that predict recurrence in stage IB and IIA cervical carcinoma patients with negative pelvic lymph nodes. Cancer 1997;80:1234-40.
38. Farley JH, Hickey KW, Carlson JW, Rose GS, Kost ER, Harrison TA. Adenosquamous histology predicts a poor outcome for patients with advanced-stage, but not earlystage, cervical carcinoma. Cancer 2003;97:2196-202.